BBIO
$70.94
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases.
Recent News
A Look At BridgeBio Pharma (BBIO) Valuation After Strong Long Term Returns And Recent Share Pullback
BridgeBio Pharma (BBIO) has drawn fresh attention after recent trading left the stock with a loss of about 8% over the past month and 7% over the past 3 months. See our latest analysis for BridgeBio Pharma. These recent pullbacks sit against a much stronger backdrop, with the share price up sharply over the past year, as reflected in a 1 year total shareholder return of 110.52% and a 3 year total shareholder return of around 4x. If this kind of biotech volatility has your attention, it could...
BridgeBio Pharma Touts Attruby Uptake, Bayer’s Europe Rollout and 2026-28 Pipeline Timelines at Leerink Conf
BridgeBio Pharma (NASDAQ:BBIO) highlighted accelerating U.S. uptake for its transthyretin (TTR) stabilizer Attruby and laid out key timelines for upcoming launches and pipeline programs during a presentation at the 2026 Leerink Partners Global Healthcare Conference. Chinmay Shukla, the company’s SVP
BridgeBio Pharma CEO Teases Pipeline Launches, Attruby Momentum, and Pfizer Tafamidis Trial Update
BridgeBio Pharma (NASDAQ:BBIO) CEO Neil Kumar discussed the company’s late-stage pipeline, commercial execution priorities, and the evolving transthyretin amyloid cardiomyopathy (ATTR-CM) market in a conversation with Barclays biotech analyst Elie Merle. Kumar also offered high-level commentary on t
BridgeBio (BBIO) Soars 13% on Double-Digit Price Target Upgrade
BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of the 10 Stocks Investors Are Watching. BridgeBio saw its share prices jump by 13.22 percent on Tuesday to close at $74.32 apiece, as investors took path from an investment firm’s double-digit price target upgrade for its stock. In a market report, JPMorgan raised its price target for BridgeBio […]
Why BridgeBio Leapfrogged Its 50-Day Line On Pfizer's Patent Shake-Up
BridgeBio stock popped Tuesday on a notable shake-up in the patent battle surrounding Pfizer's rival drug, tafamidis.